MarketPulse
N

$NUVL

2 articles found
1 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Trims $104M Nuvalent Stake as Cancer Drug Developer Surges 30%

Vestal Point Capital sold $103.93M in Nuvalent shares, reducing exposure despite company's 30% rally and $1.4B cash position awaiting 2026 FDA decisions.
ABBVNUVLTERNBMRNFDA approvalbiotech
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Cuts Nuvalent Position by $84M Despite Strong Stock Performance

Commodore Capital cuts $84M Nuvalent stake to 3.68% despite 29% stock gains. Biotech firm awaits September PDUFA decision for lead drug candidate.
RLAYNUVLFDA approvalclinical trials